Brief: Akari Therapeutics Secures Australian Patent Approval
27/04/2026 13:58
April 27 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS SECURES AUSTRALIAN PATENT APPROVAL, FURTHER EXPANDING GLOBAL PROTECTION OF ITS PROPRIETARY PH1 RNA SPLICING MODULATOR ADC PAYLOAD AKARI THERAPEUTICS PLC - AKTX-101 IN IND-ENABLING STUDIES WITH PHASE 1 TRIAL EXPECTED LATE 2026/EARLY 2027 Source text: ID:nGNX7dgdTZ Further company coverage: AKTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics